TCL Archive Chemoprevention Concept Approved By DCPC Bard Uses Biological Markers To Assess Risk Modulation September 27, 1985
TCL Archive Drug Development: Tivozanib Trial Discontinued Due to Insufficient Enrollment February 7, 2014